Clinical Trial Detail

NCT ID NCT04109924
Title TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Bevacizumab + Irinotecan + trifluridine/tipiracil hydrochloride

Age Groups: adult senior

No variant requirements are available.